92nd European Atherosclerosis Society Congress 2024
Phase 1 results on novel oral PCSK9 inhibitor, AZD0780
AZD0780, the first oral small molecule modulator of PCSK9, reduced LDL-C by more than 50% when added to rosuvastatin in participants with LDL-C >100 mg/dL (>2.6 mmol/L) to 190 mg/dL (4.9 mmol/L). Results of the Phase 1 study, presented by Dr Rick Vega (AstraZeneca, Gaithersburg,…
read more »
LIBerate-CVD supports long term lerodalcibep safety and efficacy in ASCVD
Latest data from the LIBerate trials programme of lerodalcibep, the small recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin, have demonstrated long term safety and efficacy in patients with atherosclerotic cardiovascular disease (ASCVD). In the LIBerate-CVD trial of 922 patients with…
read more »
ELIPSE study shows evinacumab efficacy by LDLR genotype and function
Evinacumab treatment results in sustained LDL-C reduction in patients with homozygous familial hypercholesterolaemia (HoFH), irrespective of LDL receptor (LDLR) genotype or function, according to a sub-analysis of data from an open label extension (OLE) of the ELIPSE study. Of the 116 patients enrolled in the…
read more »
PCSK9 inhibitor underuse reported in France
One in three people with atherosclerotic cardiovascular disease (ASCVD) in France may be untreated with lipid lowering therapy (LLT), with as few as 0.25% likely to be receiving a PCSK9 inhibitor.1 These are the findings from an analysis of information from the national health data…
read more »
